Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.67 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.67 |
| ▸ | CD69 | Q07108 | 1/20 | 0.55 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.51 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | AMY2A | P04746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533372 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL19241971 | 0.98 | LGALS3 (0.64) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL4309100 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL20555908 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL17050874 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL10524839 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL4125477 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL117333 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL14268473 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA | |
| SCHEMBL9398176 | 0.97 | LGALS3 (0.66) | LGALS3LGALS8LGALS4CD69CHIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927507-B | Method for preparing oligosaccharide by combining glycoside phosphorylase with monosaccharide kinase and polyphosphate kinase | 山东大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| US-20240115714-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-115927507-A | Method for preparing oligosaccharide by combining glycoside phosphorylase with monosaccharide kinase and polyphosphate kinase | 山东大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| US-20220068431-A1 | DECODING APPROACHES FOR PROTEIN IDENTIFICATION | NAUTILUS SUBSIDIARY, INC. | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | LGALS3 142/4885LGALS8 65/4885LGALS4 183/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
| US-20240115714-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.